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*Pneumocystis jirovecii* causes severe pneumonia in immunocompromised patients, including HIV-infected persons, transplant recipients, patients receiving high-grade chemotherapy for hemato-oncologic diseases, and persons with autoimmune diseases who are treated with immunosuppressive drugs. Cotrimoxazole, the combination of sulfamethoxazole and trimethoprim (SMX/TMP), is the drug of choice for prevention of and treatment for *Pneumocystis* pneumonia (PCP). SMX/TMP targets enzymes involved in the biosynthesis of folic acid, dihydropteroate synthase (DHPS), and dihydrofolate reductase.

Several investigators have reported an association between failure of prophylaxis when using sulfa drugs and substitutions of 2 aa within the putative sulfa binding site of DHPS at positions 55 (Thr to Ala, mutation M1) and 57 (Pro to Ser, M2) ([@R-2-1]*--*[@R-2-4]). These mutations were observed either as single (M1 or M2) or double (M3) mutation. This association strongly suggested that *P. jirovecii* DHPS mutations conferred a level of sulfa resistance sufficient to cause failure of anti-PCP prophylaxis. However, the mutations might have also conferred a clinically substantial resistance to sulfa treatment for overt PCP.

To investigate the issue, many studies have analyzed the effect of the mutations on the outcome of PCP. About half of those studies did not detect any association between the mutations and an increased risk of death caused by PCP ([@R-2-5]*--*[@R-2-8]) or a decreased response to sulfa drugs ([@R-2-3]*,*[@R-2-9]*--*[@R-2-11]). Conversely, other studies detected an association with a poor outcome ([@R-2-12]*,*[@R-2-13]): sulfa treatment failure ([@R-2-14]*,*[@R-2-15]); more severe symptoms and need of assisted ventilation ([@R-2-13]); or a trend for a worse prognosis ([@R-2-16]). Thus, the effect of these mutations on PCP outcome is unclear and justifies investigation to improve PCP treatment and prognosis.

The possibility of other parameters influencing PCP outcome has also been explored. *P. jirovecii* genotype Ne of the internal transcribed spacers (ITSs) of the nuclear rRNA operon has been associated with milder disease ([@R-2-17]), failure of PCP prophylaxis ([@R-2-18]), and failure of PCP treatment ([@R-2-9]). One ITS genotype observed in Australia was associated with reduced severity of PCP ([@R-2-13]). Specific *P. jirovecii* genotypes defined by single-nucleotide polymorphisms in 3 loci were associated with low or high burden during the course of PCP ([@R-2-19]). In comparison, some studies did not detect any associations between *P. jirovecii* genotypes, including Ne genotype, and several clinical parameters, such as severity and survival at 3 months ([@R-2-15]*,*[@R-2-20]). These observations suggested that some *P. jirovecii* genotypes might be more virulent or resistant to drugs, but further studies are needed to provide better understanding the issue.

We previously examined *P. jirovecii* DHPS polymorphisms in clinical specimens of 158 immunosuppressed patients from 5 hospitals in the city of Lyon in France ([@R-2-7]). We detected an association between DHPS mutation M2 and failure of prophylaxis when pyrimethamine/sulfadoxine was used but not between DHPS mutations and death caused by PCP. In this study, we further observed the proportion of the organisms harboring DHPS mutations (36%) and of death attributed to PCP (20%) among these 158 patients. We investigated in more detail the effect of DHPS mutations on PCP prognoses, taking into account more clinical parameters. Moreover, to test the hypothesis of variable virulence of some *P. jirovecii* genotypes, we identified those present in the specimens. Because the disease signs and symptoms vary considerably between HIV-infected and HIV-uninfected patients, we limited our analyses to the HIV-infected patients.

Patients, Materials, and Methods
================================

Patients and Specimens
----------------------

The specimens consisted of 112 bronchoalveolar lavage (BAL) samples obtained from 110 HIV-infected patients with confirmed PCP who were hospitalized in 5 university hospitals in Lyon, France. These 110 patients were a subset of the 158 patients analyzed ([@R-2-7]) who were HIV-infected and who had a medical chart complete enough to support the analyses performed in the present study ([Tables 1](#T-2-1){ref-type="table"}, [2](#T-2-2){ref-type="table"}). Two of the patients had second cases of PCP separated from their initial infections by 5 and 12 months, respectively; each was treated as an independent observation. BAL specimens were collected during April 1993 and December 1996 and were stored at --20°C before analysis. The 112 cases represented 47% of the PCP cases that occurred during this period in the 5 hospitals.

###### *Pneumocystis jiroveci* dihydropteroate synthase genotype distribution according to clinical parameters of 112 cases of pneumonia in 110 HIV-positive patients from 5 university hospitals in Lyon, France\*

  ---------------- --------------- ---------
  Characteristic   DHPS genotype   p value
  ---------------- --------------- ---------

  Wild type, n = 75                         M2, n = 17   M3, n = 20        
  ----------------------------------------- ------------ ------------ ---- ---------
  Age at PCP diagnosis, y                                                  
  1--40                                     41           10           14   0.62
  41--60                                    31           7            5    
  61--80                                    3            0            1    
  Sex                                                                      
  M                                         62           14           19   0.38
  F                                         13           3            1    
  Diagnosis year                                                           
  1993                                      6            2            0    0.58
  1994                                      24           3            4    
  1995                                      20           5            6    
  1996                                      25           7            10   
  CD4 cell count, median cells/μL†                                         
  0--50                                     42           15           11   0.05
  51--100                                   17           0            4    
  \>100                                     10           0            2    
  First-line treatment                                                     
  SMX/TMP                                   59           14           15   0.90
  Pentamidine or atovaquone                 14           3            5    
  Others                                    2            0            0    
  SMX/TMP allergy                                                          
  Yes                                       4            0            3    0.27
  No                                        71           17           17   
  Corticotherapy at PCP diagnosis                                          
  Yes                                       18           1            3    0.25
  No                                        57           16           17   
  Mechanical ventilation at PCP diagnosis                                  
  Yes                                       11           0            3    0.26
  No                                        64           17           17   
  *P. jirovecii* SSCP type 1                3            6            1    \<0.001
  7                                         3            0            6    
  10                                        2            1            1    
  Others                                    30           3            3    
  Co-infected                               37           7            9    
  Outcome within 1 month                                                   
  Favorable                                 61           16           14   0.39
  Death attributed to PCP                   12           1            5    
  Death not attributed to PCP               2            0            1    

\*Data derived from Fisher's exact test. DHPS, dihydropteroate synthase; M, mutation; SSCP, single-strand conformation polymorphism; PCP, *P. jirovecii* pneumonia; SMX/TMP, sulfamethoxazole and trimethoprim.  †Data missing for 11 patients.

###### *Pneumocystis jiroveci* SSCP genotype distribution according to clinical parameters of 112 cases of pneumonia in 110 HIV-positive patients from 5 university hospitals in Lyon, France\*

  ---------------- -------------------------- ---------
  Characteristic   *P. jirovecii* SSCP type   p value
  ---------------- -------------------------- ---------

  1, n = 10                                 7, n = 9   10, n = 4   Others, n = 36   Co-infected, n = 53        
  ----------------------------------------- ---------- ----------- ---------------- --------------------- ---- -------
  Age at PCP diagnosis, y                                                                                      
  1--40                                     8          5           2                22                    28   0.89
  41--60                                    2          4           2                13                    22   
  61--80                                    0          0           0                1                     3    
  Sex                                                                                                          
  M                                         3          1           1                6                     6    0.44
  F                                         7          8           3                30                    47   
  Diagnosis year                                                                                               
  1993                                      1          0           0                2                     5    0.90
  1994                                      3          2           2                8                     16   
  1995                                      2          2           1                9                     17   
  1996                                      4          5           1                17                    15   
  CD4 cell count, median cells/μL†                                                                             
  0--50                                     7          5           3                23                    30   0.87
  51--100                                   0          2           1                6                     12   
  \>100                                     1          1           0                5                     5    
  First-line treatment                                                                                         
  SMX/TMP                                   7          3           3                26                    49   0.001
  Pentamidine or atovaquone                 2          6           1                9                     4    
  Others                                    1          0           0                1                     0    
  SMX/TMP allergy                                                                                              
  Yes                                       0          2           0                3                     2    0.27
  No                                        10         7           4                33                    51   
  Corticotherapy at PCP diagnosis                                                                              
  Yes                                       0          4           0                7                     11   0.17
  No                                        10         5           4                29                    42   
  Mechanical ventilation at PCP diagnosis                                                                      
  Yes                                       0          2           0                2                     10   0.19
  No                                        10         7           4                34                    43   
  Outcome within 1 month                                                                                       
  Favorable                                 9          5           4                28                    45   0.44
  Death attributed to PCP                   1          4           0                6                     7    
  Death not attributed to PCP               0          0           0                2                     1    

\*Data derived from Fisher's exact test. SSCP, single-strand conformation polymorphism; PCP, *P. jirovecii* pneumonia; SMX/TMP, sulfamethoxazole and trimethoprim.  †Data missing for 11 patients.

Characteristics of Patients
---------------------------

Specific information on demographic and clinical characteristics, treatment regimens, and PCP outcome were obtained from patients' medical charts. Death within 1 month after the date of PCP diagnosis was attributed to PCP when the physician recorded it as the primary cause of death in the medical chart and on the death certificate. Failure of sulfa treatment (SMX/TMP or dapsone) was defined by occurrence of [\>]{.ul}1 of the following events within 5 days after PCP diagnosis: a change of drug treatment because of lack of clinical improvement, worsening of clinical features or gas exchange parameters, addition of corticosteroids, new need of mechanical ventilation, or death attributed to PCP. Start-of-therapy dates were available for 81 patients. Therapy was started during 1 of 3 periods: before the day on which PCP was diagnosed (n = 34, 42%); the day on which PCP was diagnosed (n = 37, 46%); or after that day (n = 10, 12%). Therapy was started most frequently 1 or 2 days before the day on which BAL was obtained (n = 26, 77% of the 34 patients whose therapy was started before PCP was diagnosed). All chart abstractions were performed without knowledge of *P. jirovecii* and DHPS genotyping results. Informed consent was obtained from all patients. Study protocols and patient consent forms were approved by the institutional review board.

DHPS and Genotyping
-------------------

DNA extraction from BAL specimens and DHPS binding site genotyping by using the PCR--single-strand conformation polymorphism (SSCP) technique were done as described ([@R-2-7]). Four DHPS SSCP patterns were observed, each corresponding to 1 of the 4 known DHPS alleles (M1, M2, M3, and wild type). *P. jirovecii* present in BAL specimens were typed as described by using PCR-SSCP of 4 variable genomic regions ([@R-2-21]). The variable regions analyzed were ITS1 of the nuclear rDNA operon, the intron of the nuclear 26S rRNA gene, the variable region of the mitochondrial 26S rRNA gene, and the region surrounding the intron no. 6 of the β-tubulin gene. In the PCR-SSCP technique, each allele is identified by a specific SSCP pattern made of 2 DNA bands, each corresponding to 1 of the 2 single strands of the allele.

Statistical Analysis
--------------------

Because of small sample sizes, we used Fisher exact tests for general association to compare proportions relative to the numbers presented in [Tables 1](#T-2-1){ref-type="table"} and [2](#T-2-2){ref-type="table"}. We estimated the 2-month survival curves after PCP by using the Kaplan-Meier method and compared those curves by using log-rank tests. Cox proportional hazards method was used to identify independent prognostic factors associated with survival. The risk factors were selected a priori based on theoretical considerations; because no deaths occurred among women, we did not include gender in the variables. Also, the variable CD4 cell count was not included because it had 1) numerous missing values (n = 11, including 3 deaths attributed to PCP), and 2) no significant association with death attributed to PCP in bivariate analysis (p = 0.09). We used logistic regression analysis to identify factors associated with sulfa treatment failure; odds ratios with 95% CIs are reported. We tested the proportionality assumption using the nonzero slope test based on the scaled Schoenfeld residuals, and checked the colinearity (mean variance inflation factor = 1.16). All statistical analyses were conducted by using STATA version 11.1 (StataCorp LP, College Station, TX, USA).

Results
=======

Specimens and Patients
----------------------

One hundred twelve BAL specimens collected from 110 HIV-infected patients in whom PCP was diagnosed were included in the study. Two of the patients had second cases of PCP. Two patients also had tuberculosis, and 1 had histoplasmosis; each of the 3 recovered from PCP. The cohort ranged in age from 4--69 years (median 37 years); 94 (85%) were men. The most common risk factor for HIV was homosexuality (41%); the next most common risk factor was intravenous drug use (8%). CD4 counts at the diagnosis of PCP were documented in the medical charts of 101 patients and ranged from 0 to 390/μL (median 24). In 2 cases, patients had CD4 cell counts \>200 cells/µL (242 and 390).

Detection of DHPS Alleles by using PCR-SSCP
-------------------------------------------

We previously genotyped the *P. jirovecii* DHPS binding site from the 112 BAL specimens by PCR amplification of a region of 318 bp, then SSCP ([@R-2-7]). To simplify the analyses, specimens that contained a mixture of wild type and mutant DHPS genotypes (n = 11) were classified in the corresponding mutant category. For most of the cases, the patients harbored *P. jirovecii* with wild type DHPS (n = 75, 67.0%). Seventeen (15.2%) episodes involved a M2 mutant DHPS genotype, and 20 (17.8%) involved a M3 allele. The overall proportion of cases in which the patient had mutant DHPS was 33.0% (n = 37). There was a variation of this proportion from 25% to 57% among the 5 hospitals, but the difference did not reach statistical significance ([@R-2-7]). No significant differences (p = 0.05) were found between patients who harbored *P. jirovecii* with DHPS mutations and those who did not for all the demographic or clinical characteristics analyzed.

Genotyping by Using PCR-SSCP
----------------------------

Twenty-seven *P. jirovecii* genotypes were identified among the 112 BAL specimens by using the multitarget PCR-SSCP typing method ([@R-2-21]). Fifty-nine (52.7%) specimens contained a single *P. jirovecii* type, 47 (42.0%) specimens contained 2 types, and 6 (5.3%) specimens contained more than 2 types that could not be identified. The 5 most prevalent genotypes were type 1 (n = 29 occurrences), type 7 (n = [@R-2-15]), type 10 (n = [@R-2-12]), type 2 (n = [@R-2-10]), and type 6 (n = [@R-2-10]). The 2 patients who had 2 cases each of PCP were infected with different types for each case, suggesting possible de novo infection for each case, rather than reactivation of the type that caused the first case.

Associations between DHPS and *P. jirovecii* SSCP Genotypes and between Each Genotype and Clinical Factors
----------------------------------------------------------------------------------------------------------

Possible associations between DHPS and *P. jirovecii* SSCP genotypes and between each DHPS and *P. jirovecii* SSCP genotype and the clinical factors were investigated for the 112 PCP cases ([Tables 1](#T-2-1){ref-type="table"}, [2](#T-2-2){ref-type="table"}). Specimens co-infected with [\>]{.ul}2 *P. jirovecii* SSCP types were gathered into a specific category, and the 3 most prevalent types among specimens containing a single genotype were considered separately. The sample was stratified into 5 groups: type 1, type 7, type 10, other types, and co-infected specimens. The DHPS mutations were not distributed evenly among the *P. jirovecii* SSCP type (p\<0.001, by Fisher exact test) ([Table 1](#T-2-1){ref-type="table"}), type 7 being associated with genotype M3 (66.7% of the types 7). The DHPS mutations were also unevenly distributed among the CD4 cell count groups (p = 0.05); mutation M2 was associated with \<50 cells/μL (100%). Finally, the first-line treatment varied significantly according to the *P. jirovecii* SSCP type (p = 0.001) ([Table 2](#T-2-2){ref-type="table"}), type 7 being most often treated with pentamidine or atovaquone rather than SMX/TMP (66.7%).

Predictors of Death Attributed to PCP
-------------------------------------

Of the 112 observed cases in this study, 21 (18.8%) patients died within 1 month. PCP was identified as the cause of death for 18 patients. Because of the small number of observations, the categories *P. jirovecii* type 10 and others types were further grouped with co-infected specimens, forming 3 groups: type 1, type 7, and other types. Bivariate analyses revealed that *P. jirovecii* SSCP type 7 and the need for mechanical ventilation at PCP diagnosis were possible predictors of death attributed to PCP (log-rank test, p = 0.08 and p\<0.0001, respectively) ([Figure](#F-2-1){ref-type="fig"}). No effect of the DHPS mutated alleles on the PCP mortality rate was observed within 1 month (p = 0.35). Because type 7 was associated with DHPS mutation M3 and with first-line treatment with pentamidine or atovaquone, we included these variables in a multivariable analysis ([Table 3](#T-2-3){ref-type="table"}). This analysis showed that type 7 and the need for mechanical ventilation at PCP diagnosis were significantly associated with an increased risk of death caused by PCP (relative hazard = 4.2, 95% CI 1.0--17.9, p = 0.05, and relative hazard = 5.0, 95% CI 1.8--13.5, p = 0.002, respectively) ([Table 3](#T-2-3){ref-type="table"}). Similar results were obtained when the DHPS genotype variable was removed from the model.

![Kaplan-Meier survival plots for 4 variables of 112 *Pneumocystis* pneumonia cases. A) p = 0.08; B) p = 0.35; C) p = 0.60; D) p = 0.0001. DHPS, dihydropteroate synthase.](12-0140-F){#F-2-1}

###### Multivariate analysis of risk factors for death attributed to PCP among 112 cases in 110 patients from 5 university hospitals, Lyon, France

  Risk factor                               Death attributed to PCP   Adjusted RH (95% CI)†   p value           
  ----------------------------------------- ------------------------- ----------------------- ----------------- -------
  *P. jirovecii* PCR-SSCP type                                                                                  
  7                                         4                         5                       4.2 (1.0--17.9)   0.05
  Others                                    14                        89                      1.0 (Reference)   
  Mechanical ventilation at PCP diagnosis                                                                       
  Yes                                       8                         6                       5.0 (1.8--13.5)   0.002
  No                                        10                        88                      1.0 (Reference)   
  DHPS genotype                                                                                                 
  M3                                        5                         15                      1.1 (0.4--3.4)    0.82
  M2                                        1                         16                      0.6 (0.08--5.1)   0.66
  Wild type                                 12                        63                      1.0 (Reference)   
  Mean age at PCP diagnosis, y              38.5                      40.6                    1.0               0.95
  First-line treatment                                                                                          
  Others                                    3                         19                      0.4 (0.1--2.0)    0.29
  Sulfonamides                              15                        75                      1.0 (Reference)   

\*PCP, *Pneumocystis jirovecii* pneumonia; RH, relative hazard; SSCP, single-strand conformation polymorphism; DHPS, dihydropteroate synthase; M, mutation. †RH for death attributed to PCP after adjustment for the 5 variables presented in the table. The global p value of the test for proportionality was 0.55, and no individual test was statistically significant at the 0.05 level.

Predictors of Sulfa Drug Treatment Failure
------------------------------------------

To treat most cases, the patients received a sulfa drug as first-line treatment: for 88 (78.6%) cases, patients were treated with SMX/TMP, and for 2 (1.8%) cases, patients were treated with dapsone. Adverse effects of SMX/TMP in 5 patients led to a therapy change that excluded them from the analysis. Among the remaining 85 cases, 30 patients (35.3%) did not respond to the sulfa treatment at 5 days. Multivariate analysis of the same variables as for the analysis of predictors of death caused by PCP, except the first-line treatment, showed that an increased risk of failure of sulfa treatment was associated with the need for mechanical ventilation at PCP diagnosis (odds ratio 34.2, 95% CI 3.6--321.3, p = 0.002).

Discussion
==========

Analysis of the parameters of 112 PCP cases in HIV-infected patients involving a high proportion of *P. jirovecii* DHPS mutations and deaths attributed to PCP did not show an association between these mutations and a worse PCP outcome. This observation contrasts with studies that reported some negative influence of these mutations on PCP prognosis ([@R-2-12]*--*[@R-2-15]) but converges with results of other studies reporting no effect ([@R-2-3]*,*[@R-2-5]*--*[@R-2-11]). The lack of standardization of the outcome parameters analyzed in the different studies, the confounders used for adjustment, and the small number of cases in some investigations might explain these conflicting conclusions. Nevertheless, a strong effect would have been identified even in studies with restricted sample sizes, suggesting that if these mutations have any effect on PCP outcome, it is small. Studies in the model organisms *Saccharomyces cerevisiae* ([@R-2-22]) and *Escherichia coli* ([@R-2-23]) strongly suggested that DHPS mutations confer some level of sulfa resistance to *P. jirovecii*. However, these reports did not speculate whether this level is sufficient to provoke clinical failure of sulfa treatment.

*P. jirovecii* type 7 was independently associated (i.e., nonnull partial correlation) with an increased risk for death caused by PCP. However, this type was also associated with DHPS mutation M3 (66.7% of the single infections), suggesting that the combination of the 2 parameters might have been necessary for its pathogenicity, even if mutation M3 alone was not a predictor of death caused by PCP. Consequently, we cannot exclude the role of mutation M3 for the increased virulence of *P. jirovecii* PCR-SSCP type 7. Type 7 was also associated with first-line treatment with pentamidine or atovaquone rather than SMX/TMP, suggesting that use of these less effective drugs might have contributed to an increased number of deaths of patients infected with type 7. However, the proportion of deaths attributed to PCP among these patients was higher with SMX/TMP than with pentamidine or atovaquone (2 of 3 vs. 2 of 6 patients, respectively). *P. jirovecii* PCR-SSCP type 7 has not been reported to have a higher virulence than the other types. *P. jirovecii* ITSs type B2a1, as well as other genotypes, were suggested to have higher and modified virulence ([@R-2-9]*,*[@R-2-13]*,*[@R-2-17]*--*[@R-2-19]).

We observed that the need for mechanical ventilation at PCP diagnosis was associated with an increased risk for death caused by PCP, as was failure of sulfa treatment. An association of this comorbidity factor with an increased risk for death has already been reported ([@R-2-24]*,*[@R-2-25]). Several other clinical parameters were reported to be predictors for death caused by PCP in HIV-infected patients ([@R-2-26]), and a scoring tool was recently proposed ([@R-2-27]). Host polymorphisms within receptors involved in the immune response have also been reported to be related to *P. jirovecii* infection ([@R-2-28]*,*[@R-2-29]*).* This study confirms that certain *P. jirovecii* genotypes might have different pathogenic traits. Further studies of PCR-SSCP type 7 could help understanding of *P. jirovecii* virulence and drug resistance by clinicians and public health professionals.
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CME Questions
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**1. You are seeing a 30-year-old man with HIV infection and a new diagnosis of *Pneumocystis jirovecii* pneumonia (PCP). You are concerned regarding the possibility of genetic mutations in this organism. What was the overall rate of dihydropteroate synthase (DHPS) mutations among cases of PCP in the current study?**

A. 4%

B. 33%

C. 74%

D. 83%

**2. DHPS mutations were most associated with which of the following patient characteristics in the current study?**

A. CD4 count less than 50 cells/μL

B. Age over 40 years

C. Male sex

D. Diagnosis of PCP after 1995

**3. You initiate treatment with trimethoprim-sulfamethoxazole. Which of the following variables was most associated with sulfa resistance of *P. jirovecii* in the current study?**

A. Need for mechanical ventilation at the time of PCP diagnosis

B. *P. jirovecii* type 10

C. *P. jirovecii* type 7

D. DHPS M2 mutation

**4. Which of the following variables was most associated with a higher risk of death due to PCP in the current study?**

A. DHPS M2 mutation

B. DHPS M3 mutation

C. *P. jirovecii* type 7

D. Older age
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  **4. The activity was presented objectively and free of commercial bias.**               
  Strongly Disagree                                                                        Strongly Agree
  1                                                                            2   3   4   5
  ---------------------------------------------------------------------------- --- --- --- ----------------
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